Cervical carcinoma in the setting of uterovaginal prolapse: comparing standard versus tailored management.
PD-L1
cervical cancer
procidentia
uterovaginal prolapse
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
01
2020
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
23
6
2020
Statut:
epublish
Résumé
Cervical cancer in the setting of uterovaginal prolapse is exceedingly rare. Altered anatomy can complicate treatment of underlying cancer. We first present a rare case of cervical cancer with invasion of uterovaginal prolapse as well as a systematic review of similar reported cases in the literature. The objective of this study was to compare the practice patterns and outcomes regarding cervical cancer with invasion of procidentia. We conducted a systematic search of online databases (PubMed, Embase, Medline and the Cochrane Library) from 1990 to 2018 of all the cases of cervical cancer associated with stage III-IV uterovaginal prolapse. Patient demographics, pathology, surgical management, chemotherapy, radiation and disease-free survival were compared. Fifteen reported cases of cervical cancer in the setting of procidentia were identified (squamous cell carcinoma-14, clear cell carcinoma-1). The mean age at diagnosis was 74 years (range 54-89). Thirteen percent ( Cervical cancer in the setting of stage III-IV uterovaginal prolapse can be managed successfully with standard treatment strategies (primary surgery with adjuvant therapy as necessary versus chemoradiation). When patients are surgical candidates, techniques to address the underlying prolapse can be used for symptomatic improvement.
Identifiants
pubmed: 32565896
doi: 10.3332/ecancer.2020.1043
pii: can-14-1043
pmc: PMC7289612
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1043Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Eur J Surg Oncol. 2017 Apr;43(4):725-734
pubmed: 28215507
Gynecol Oncol Rep. 2018 Aug 16;26:14-16
pubmed: 30148199
Eur J Cancer Care (Engl). 2010 Jul;19(4):548-50
pubmed: 19694800
Eur J Gynaecol Oncol. 2008;29(3):272-5
pubmed: 18592794
J Am Geriatr Soc. 2012 Sep;60(9):1775-7
pubmed: 22985150
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004014
pubmed: 23633316
Ann Diagn Pathol. 2009 Oct;13(5):344-6
pubmed: 19751912
Gynecol Oncol. 2002 Feb;84(2):349-50
pubmed: 11812100
Arch Gynecol Obstet. 2010 Jul;282(1):63-7
pubmed: 20405294
Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):463-4
pubmed: 8717582
Am J Obstet Gynecol. 2018 Dec;219(6):621-622
pubmed: 29852160
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
BMJ Case Rep. 2015 May 24;2015:
pubmed: 26009601
Arch Gynecol Obstet. 2017 Jun;295(6):1303-1304
pubmed: 28444514
Prog Urol. 2014 Jun;24(8):533-4
pubmed: 24875573
Obstet Gynecol. 1963 Nov;22:606-9
pubmed: 14082280